ProfileGDS5678 / 1429564_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 72% 72% 78% 72% 75% 72% 71% 71% 71% 71% 73% 72% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5497872
GSM967853U87-EV human glioblastoma xenograft - Control 24.6501272
GSM967854U87-EV human glioblastoma xenograft - Control 34.5768872
GSM967855U87-EV human glioblastoma xenograft - Control 45.5118678
GSM967856U87-EV human glioblastoma xenograft - Control 54.5262872
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9115875
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5411172
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.4483571
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.5322571
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4925871
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4544571
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7146673
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.534372
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3512570